Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin after heart transplantation
ACTRN12622000978763Phase 3Recruiting
- Sponsor
- Garvan Institute of Medical Research
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in post-transplantation diabetes mellitus (PTDM), nephropathy and cardiac allograft dysfunction (CAD), sponsored by Garvan Institute of Medical Research. Primary endpoint: Change in glycaemia. Started Nov 2022; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
post-transplantation diabetes mellitus (PTDM)nephropathycardiac allograft dysfunction (CAD)
Beyond the preview
Go deeper on ACTRN12622000978763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000978763.